The Fort Worth Press - Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D

USD -
AED 3.672499
AFN 66.498782
ALL 80.629676
AMD 365.091035
AOA 917.000408
ARS 1492.336499
AUD 1.414877
AWG 1.80125
AZN 1.701052
BAM 1.691649
BBD 2.00813
BDT 123.418242
BHD 0.375989
BIF 2985.079791
BMD 1
BND 1.277602
BOB 11.849673
BRL 5.083698
BSD 0.997016
BTN 94.875232
BWP 13.457596
BYN 2.968819
BYR 19600
BZD 2.00519
CAD 1.39518
CDF 2262.499098
CHF 0.808199
CLF 0.023198
CLP 912.999827
CNY 6.747602
CNH 6.743155
COP 3157.68
CRC 453.228387
CUC 1
CUP 26.5
CVE 95.372573
CZK 20.984797
DJF 177.546166
DKK 6.46806
DOP 58.20179
DZD 132.308956
EGP 49.569799
ERN 15
ETB 160.923669
EUR 0.86521
FJD 2.20855
FKP 0.74148
GBP 0.741195
GEL 2.610161
GGP 0.74148
GHS 11.700039
GIP 0.74148
GMD 73.496802
GNF 8756.649224
GTQ 7.607144
GYD 208.588851
HKD 7.845875
HNL 26.723176
HRK 6.519601
HTG 130.363707
HUF 314.212956
IDR 17801
ILS 2.99985
IMP 0.74148
INR 95.21055
IQD 1306.058902
IRR 1375550.000465
ISK 123.37984
JEP 0.74148
JMD 158.335856
JOD 0.708953
JPY 157.888997
KES 128.789741
KGS 87.449779
KHR 4049.647537
KMF 425.999543
KRW 1411.360366
KWD 0.30866
KYD 0.830861
KZT 467.275008
LAK 22510.919863
LBP 89282.792025
LKR 334.420274
LRD 179.959348
LSL 16.197552
LTL 2.95274
LVL 0.60489
LYD 6.341738
MAD 9.29222
MDL 17.337716
MGA 4254.638239
MKD 53.219738
MMK 2099.549369
MNT 3595.852714
MOP 8.056654
MRU 40.080439
MUR 46.795264
MVR 15.450064
MWK 1728.841413
MXN 17.138497
MYR 4.085099
MZN 63.904996
NAD 16.197552
NGN 1361.789707
NIO 36.690741
NOK 9.50157
NPR 151.800372
NZD 1.69811
OMR 0.382693
PAB 0.997016
PEN 3.376465
PGK 4.406003
PHP 60.814978
PKR 276.796523
PLN 3.719555
PYG 5928.296501
QAR 3.644596
RON 4.541503
RSD 101.492021
RUB 81.61994
RWF 1466.072741
SAR 3.744756
SBD 8.065696
SCR 14.449077
SDG 600.504962
SEK 9.48365
SGD 1.278665
SLE 24.60377
SOS 569.822255
SRD 37.866499
STD 20697.981008
STN 21.191022
SVC 8.723782
SZL 16.194265
THB 32.970555
TJS 9.197509
TMT 3.51
TND 2.929032
TRY 47.714698
TTD 6.757774
TWD 32.250104
TZS 2643.563029
UAH 44.653894
UGX 3714.050945
UYU 40.133201
UZS 11924.058297
VES 755.762399
VND 26204.5
VUV 118.557141
WST 2.733716
XAF 567.363231
XAG 0.015658
XAU 0.00023
XCD 2.70255
XCG 1.796912
XDR 0.705618
XOF 567.363231
XPF 103.152705
YER 238.395817
ZAR 16.14803
ZMK 9001.197294
ZMW 18.818492
ZWL 321.999592
  • CMSC

    0.0240

    21.744

    +0.11%

  • BCC

    2.3400

    86.6

    +2.7%

  • BCE

    -0.0200

    22.75

    -0.09%

  • JRI

    0.1500

    12.81

    +1.17%

  • RIO

    1.4500

    101.1

    +1.43%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • GSK

    0.7900

    52.96

    +1.49%

  • BTI

    0.6000

    59.33

    +1.01%

  • NGG

    0.4700

    80.88

    +0.58%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • RELX

    0.0485

    35.52

    +0.14%

  • BP

    -0.6000

    41.63

    -1.44%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • VOD

    0.1900

    16.19

    +1.17%

  • AZN

    1.4100

    161.42

    +0.87%

Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D
Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D

Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D

Veteran life sciences leader to drive enterprise growth and expand adoption of AI-ready data solutions across pharma and biotech

Text size:

SAN DIEGO, CA / ACCESS Newswire / March 25, 2026 / Rancho BioSciences today announced the appointment of Chris O'Brien as Chief Executive Officer. O'Brien will lead the company's next phase of growth as Rancho expands adoption of its AI-ready data solutions across pharmaceutical, biotechnology, and research organizations.

Rancho BioSciences delivers AI-ready data solutions that transform fragmented biomedical data into standardized, reusable assets for AI, analytics, and machine learning. As life sciences organizations continue investing in AI and advanced analytics, preparing inconsistent and siloed data remains a major bottleneck-often slowing analysis and limiting reuse across programs. Rancho addresses this by standardizing and harmonizing complex data so it can be used immediately and consistently across the R&D lifecycle.

O'Brien brings more than 20 years of leadership experience building and scaling organizations across the life sciences and research services ecosystem. Most recently, he served as Chief Executive Officer of Biorasi, where he led global clinical research operations supporting emerging biotech and pharmaceutical companies. Earlier, he served as President and Chief Operating Officer of Decision Resources Group and founded Linchpin Partnerships, advising organizations on growth strategy and strategic partnerships. He holds an MBA from the Tuck School of Business at Dartmouth and a BA from Middlebury College.

As CEO, O'Brien will focus on accelerating the expansion of Rancho's portfolio of data and AI-enabled solutions, strengthening operational rigor across the organization, and driving growth across enterprise accounts. A key priority will be scaling Rancho's platform capabilities to support larger, more strategic engagements, while improving efficiency, predictability, and speed across both the commercial and delivery lifecycle.

"Chris brings the leadership and operational experience we need to grow Rancho's impact in a rapidly evolving market," said Julie Bryant, founder and Chief Strategy Officer of Rancho BioSciences. "Our clients are no longer asking for one-off data projects-they need AI data strategy and execution partners who can deliver repeatable, future-proof solutions that can be applied across programs and therapeutic areas. Chris understands how to scale that kind of delivery while maintaining the scientific rigor our clients expect."

"I'm excited to join Rancho Biosciences at this pivotal moment," said Chris O'Brien. "The increasing complexity and volume of scientific data and the rapid adoption of AI create a clear need for trusted partners who can deliver structured, high-quality data and actionable insights at enterprise scale. Julie Bryant and Rancho have built a strong foundation, and I look forward to working with the team to expand our impact, deepen client partnerships, drive sustained growth and help bring life-saving medicines to patients in need."

"Chris brings the leadership and execution focus required to scale Rancho into its next phase," said Ray Hill, Operating Partner at Arsenal Capital Partners. "His experience building high-performing teams and driving commercial discipline, combined with a deep understanding of the life sciences R&D ecosystem, will be instrumental in advancing Rancho's growth strategy and delivering long-term value to clients."

Chris's appointment reinforces Rancho's strategic focus on building a scaled, science-led data and AI platform that enables life sciences organizations to improve decision-making and increase R&D productivity. The company will continue to invest in its core capabilities, data assets, and strategic alliances to support long-term, durable growth.

About Rancho BioSciences
Rancho BioSciences delivers AI-ready data solutions that enable life sciences organizations to standardize, integrate, and reuse complex biomedical data across the R&D lifecycle. With more than 150 scientists, data engineers, and bioinformatics specialists, Rancho supports faster, more reliable analytics and AI-driven decision-making across discovery, translational research, and clinical development. The company's expertise spans data engineering, scientific curation, bioinformatics, data science, and strategic data initiatives. Rancho is driven by its mission of Saving Lives Through Data.

Contact Information

Jonathan Amir (VP, Marketing): [email protected]

SOURCE: Rancho BioSciences, LLC



View the original press release on ACCESS Newswire

S.Jordan--TFWP